EN
0
Home > Products > Pharmaceuticals & Life Science > Biotechnology & Diagnostics > 2',3'-Dideoxyinosine
2',3'-Dideoxyinosine structure, CAS 69655-05-6

2',3'-Dideoxyinosine

CAS Number69655-05-6

Synonyms9-[(2R,5S)-5-(hydroxyméthyl)tétrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; DDI; Videx; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydro-2-furanyl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-9H-purin-6-ol; MFCD00077728; VIDEX EC; 2',3'-Dideoxyinosine; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; Dideoxyinosine; Didanosine; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-on; didanosinum [INN_la]

Molecular FormulaC10H12N4O3

Molecular Weight236.23

Purity98%

Density1.8±0.1 g/cm3

Boiling Point531.2±60.0 °C at 760 mmHg

Melting Point193-195 °C

Flash Point

AppearanceWhite crystalline powder

EINECS

MSDSChineseEnglish

SymbolTransport

Signal WordWarning

Cat. No.: 2A-9001681 Purity: 98%
Change View

Please Login or Create an Account to: See VlP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

Inquiry

Quality Control of [ 69655-05-6 ] Purity: 98% SDS Specification MoL

COA NMR CNMR HPLC LC-MS
Chemical & Physical Properties
CAS Number69655-05-6
Catalog No.2A-9001681
Chinese Name地达诺辛
Synonyms9-[(2R,5S)-5-(hydroxyméthyl)tétrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; DDI; Videx; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydro-2-furanyl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-9H-purin-6-ol; MFCD00077728; VIDEX EC; 2',3'-Dideoxyinosine; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; Dideoxyinosine; Didanosine; 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-on; didanosinum [INN_la]
Molecular FormulaC10H12N4O3
Molecular Weight236.23
Purity98
Density1.8±0.1 g/cm3
Boiling Point531.2±60.0 °C at 760 mmHg
Melting Point193-195 °C
AppearanceWhite crystalline powder
Water Solubility1-5 g/100 mL at 21 ºC
Storage ConditionStore in a sealed container in a cool, dry place.
ApplicationDidanosine (Videx) is a reverse transcriptase inhibitor with an IC50 of 490nM.
HTC2942000000
PubChem ID329749572
MDL NumberMFCD00077728
SMILESOC[C@@H]1CC[C@@H](O1)n2cnc3C(=O)NC=Nc23
InChI1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
InChI KeyBXZVVICBKDXVGW-NKWVEPMBSA-N
Beilstein/REAXYS3619529
NACRES CodeNA.24
UNSPSC41116107
Hazard SymbolsTransport
MSDSmsds/1681_1_69655_05_6.pdf
BioactivityDidanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.Target: NRTIs; HIVDidanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2]. Related Catalog Signaling Pathways >> Anti-infection >> HIV Signaling Pathways >> Anti-infection >> Reverse Transcriptase Research Areas >> Infection References [1]. Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35. [2]. Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71. Chemical & Physical Properties Density 1.8±0.1 g/cm3 Boiling Point 531.2±60.0 °C at 760 mmHg Melting Point 193-195 °C Molecular Formula C10H12N4O3 Molecular Weight 236.227 Flash Point 275.0±32.9 °C Exact Mass 236.090942 PSA 93.03000 LogP -1.31 Vapour Pressure 0.0±1.5 mmHg at 25°C Index of Refraction 1.798 InChIKey BXZVVICBKDXVGW-NKWVEPMBSA-N SMILES O=c1[nH]cnc2c1ncn2C1CCC(CO)O1 Storage condition 2-8°C Stability Stable. Combustible. Incompatible with strong oxidizing agents. Water Solubility 1-5 g/100 mL at 21 ºC
Use ofProperties Articles85 Name didanosine Synonym More Synonyms 2',3'-Dideoxyinosine Biological Activity Related Catalog Signaling Pathways >> Anti-infection >> HIV Signaling Pathways >> Anti-infection >> Reverse Transcriptase Research Areas >> Infection References [1]. Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35. [2]. Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71. Chemical & Physical Properties Molecular Formula C10H12N4O3 Exact Mass 236.090942 PSA 93.03000 LogP -1.31 Index of Refraction 1.798 InChIKey BXZVVICBKDXVGW-NKWVEPMBSA-N Stability Stable. Combustible. Incompatible with strong oxidizing agents.
Transport InfoProduct name: Purity: 98.0%
MSDS Transport InfoModule 14. Shipping information 14.1 UN number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: No dangerous goods IMDG Code: No dangerous goods International Air Transport Dangerous Regulations: No dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available
Related Products in Biotechnology & Diagnostics
2',3',5'-Triacetylinosine3181-38-22A-9001622
2',3',5'-Triacetyluridine4105-38-82A-9001623
2',3',5'-Tri-O-acetyladenosine7387-57-72A-9001632
2',3'-Dideoxyadenosine4097-22-72A-9001679
2',3'-Dideoxycytidine7481-89-22A-9001680
2-Aminoadenosine2096-10-82A-9002439
2'-Chloro-2'-deoxycytidine10212-19-82A-9002790
2'-Chloro-2'-deoxyuridine4753-04-22A-9002791
2-Chloroadenosine146-77-02A-9002972
2-Chloroadenosine hemidydrate81012-94-42A-9002973
Browse all Biotechnology & Diagnostics products »
Contact Us

Phone:

630-322-8886

630-322-8887

Email:

[email protected]

Office Locations:

Chicago, IL, USA

San Francisco, CA, USA